Company / R&D Expense
aTYR PHARMA INC R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$60.2M
FY2025
5-year range
$14.0M / $60.2M
FY2021-FY2025
Trend
+10.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 4 consecutive years, from $14M in FY2021 to $60M in FY2025.
Based on SEC 10-K filings.
$60M in FY2025 with a 5-year CAGR of +24.2%.
Improved from $23M to $60M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +51.6%
- 5-Year CAGR
- +24.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- aTYR PHARMA INC's r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +24.2%, indicating consistent growth.
- In FY2025, r&d expense increased 10.8% year-over-year.
- Lowest r&d expense in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $60.2M | +10.8% |
| FY2024 | $54.4M | +133.7% |
| FY2023 | $23.3M | +34.5% |
| FY2022 | $17.3M | +23.1% |
| FY2021 | $14.0M | -31.1% |
| FY2020 | $20.4M | -32.2% |
| FY2019 | $30.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026